A. Yelekbayev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. Yelekbayev has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- D. Tuleuova
JSC “Kazakh Institute of Oncology and Radiology
4 shared publications - G. Serikbayev
«Kazakh Institute of Oncology and Radiology» JSC
3 shared publications - А. Kurmanalyev
«Kazakh Institute of Oncology and Radiology» JSC
3 shared publications - N. Moldakhanova
Kazakh Institute of Oncology and Radiology
2 shared publications - Zh. Pyssanova
JSC “Kazakh Institute of Oncology and Radiology
2 shared publications - Zhandos Burkitbayev
National Research Oncology Center
2 shared publications
Latest Publications
- Open Access
- 15 April 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 75 (1) , 59-68
EPIDEMIOLOGICAL STATUS OF SOFT TISSUE SARCOMAS IN THE REPUBLIC OF KAZAKHSTAN IN 2013-2023
Relevance: Soft tissue sarcomas (STSs) are rare, aggressive malignant neoplasms that arise from mesenchymal tis-sues. They account for no more than 1% of all malignant tumors, can develop at any age, and are more common in mid-dle-aged and older people.The study aimed to obtain a complete epidemiological picture of soft tissue sarcomas in the Republic of Kazakhstan for 11 years, including data analysis for 2023. It considered various parameters such as age, gender, ethnicity, region, and tumor type.Methods: The presented study included all patients registered in the national cancer registry of Kazakhstan from 2013 to 2023, with a diagnosis of STS (ICD-10 code: C49). The number of STS cases is presented as absolute crude rates per 100,000 population. Standardized morbidity and mortality rates were calculated using the World standard.Results: From 2013 to 2023, 4697 cases of STS were reported, with an average increase in incidence of 13%. The STS incidence was 2.4 cases per 100 thousand population. In terms of prevalence among other types of cancer, STSs ranked 19th in incidence and 18th in mortality and were not among the top 10 causes of mortality and morbidity. The incidence rate of STS for both sexes was 2.1 per 100 thousand population; mortality was 0.8 per 100 thousand popula-tion. Morbidity and mortality were higher among men compared to women by 30% and 35%, respectively. Peaks in the incidence of STS were observed in the age groups 55-64 years (23.6% of cases) and 65-74 years (24%). Mortality from STS was observed in the age groups 55-64 years (24.3% of cases) and 65-74 years (17.5%).Conclusion: STSs are varied, and their diagnosis can be difficult in the early stages. The increasing incidence with age, especially in middle-aged people, emphasizes the importance of active prevention and early diagnosis in older peo-ple.
- 15 April 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 75 (1) , 59-68
Open AccessEPIDEMIOLOGICAL STATUS OF SOFT TISSUE SARCOMAS IN THE REPUBLIC OF KAZAKHSTAN IN 2013-2023
Relevance: Soft tissue sarcomas (STSs) are rare, aggressive malignant neoplasms that arise from mesenchymal tis-sues. They account for no more than 1% of all malignant tumors, can develop at any age, and are more common in mid-dle-aged and older people.The study aimed to obtain a complete epidemiological picture of soft tissue sarcomas in the Republic of Kazakhstan for 11 years, including data analysis for 2023. It considered various parameters such as age, gender, ethnicity, region, and tumor type.Methods: The presented study included all patients registered in the national cancer registry of Kazakhstan from 2013 to 2023, with a diagnosis of STS (ICD-10 code: C49). The number of STS cases is presented as absolute crude rates per 100,000 population. Standardized morbidity and mortality rates were calculated using the World standard.Results: From 2013 to 2023, 4697 cases of STS were reported, with an average increase in incidence of 13%. The STS incidence was 2.4 cases per 100 thousand population. In terms of prevalence among other types of cancer, STSs ranked 19th in incidence and 18th in mortality and were not among the top 10 causes of mortality and morbidity. The incidence rate of STS for both sexes was 2.1 per 100 thousand population; mortality was 0.8 per 100 thousand popula-tion. Morbidity and mortality were higher among men compared to women by 30% and 35%, respectively. Peaks in the incidence of STS were observed in the age groups 55-64 years (23.6% of cases) and 65-74 years (24%). Mortality from STS was observed in the age groups 55-64 years (24.3% of cases) and 65-74 years (17.5%).Conclusion: STSs are varied, and their diagnosis can be difficult in the early stages. The increasing incidence with age, especially in middle-aged people, emphasizes the importance of active prevention and early diagnosis in older peo-ple.
- Open Access
- 31 March 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 75 (1) , 59-68
EPIDEMIOLOGICAL STATUS OF SOFT TISSUE SARCOMAS IN THE REPUBLIC OF KAZAKHSTAN IN 2013-2023
Relevance: Soft tissue sarcomas are rare, aggressive malignant neoplasms that arise from mesenchymal tissues. They account for no more than 1% of all malignant tumors, can develop at any age, and are more common in middle-aged and older people. The study aimed to obtain a complete epidemiological picture of soft tissue sarcomas in the Republic of Kazakhstan for 11 years, including data analysis for 2023. It considered various parameters such as age, gender, ethnicity, region, and tumor type. Methods: The presented study included all patients registered in the national cancer registry of Kazakhstan from 2013 to 2023, with a diagnosis of soft tissue sarcoma (ICD-10 code: C49). The number of soft tissue sarcomas cases is presented as absolute crude rates per 100,000 population. Standardized morbidity and mortality rates were calculated using the World standard. Results: From 2013 to 2023, 4697 cases of soft tissue sarcomas were reported, with an average increase in incidence of 13%. The incidence of soft tissue sarcomas was 2.4 cases per 100 thousand population. In terms of prevalence among other types of cancer, incidence ranked 19th, and mortality ranked 18th and was not among the top 10 causes of mortality and morbidity. The incidence rate of STS for both sexes was 2.1 per 100 thousand population; mortality was 0.8 per 100 thousand population. Morbidity and mortality were higher among men compared to women by 30% and 35%, respectively. Peaks in the incidence of STS were observed in the age groups 55-64 years (23.6% of cases) and 65-74 years (24%). Mortality from STS was observed in the age groups 55-64 years (24.3% of cases) and 65-74 years (17.5%). Conclusion: SMTs are varied, and their diagnosis can be difficult in the early stages. The increasing incidence with age, especially in middle-aged people, emphasizes the importance of active prevention and early diagnosis in older people.
- 31 March 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 75 (1) , 59-68
Open AccessEPIDEMIOLOGICAL STATUS OF SOFT TISSUE SARCOMAS IN THE REPUBLIC OF KAZAKHSTAN IN 2013-2023
Relevance: Soft tissue sarcomas are rare, aggressive malignant neoplasms that arise from mesenchymal tissues. They account for no more than 1% of all malignant tumors, can develop at any age, and are more common in middle-aged and older people. The study aimed to obtain a complete epidemiological picture of soft tissue sarcomas in the Republic of Kazakhstan for 11 years, including data analysis for 2023. It considered various parameters such as age, gender, ethnicity, region, and tumor type. Methods: The presented study included all patients registered in the national cancer registry of Kazakhstan from 2013 to 2023, with a diagnosis of soft tissue sarcoma (ICD-10 code: C49). The number of soft tissue sarcomas cases is presented as absolute crude rates per 100,000 population. Standardized morbidity and mortality rates were calculated using the World standard. Results: From 2013 to 2023, 4697 cases of soft tissue sarcomas were reported, with an average increase in incidence of 13%. The incidence of soft tissue sarcomas was 2.4 cases per 100 thousand population. In terms of prevalence among other types of cancer, incidence ranked 19th, and mortality ranked 18th and was not among the top 10 causes of mortality and morbidity. The incidence rate of STS for both sexes was 2.1 per 100 thousand population; mortality was 0.8 per 100 thousand population. Morbidity and mortality were higher among men compared to women by 30% and 35%, respectively. Peaks in the incidence of STS were observed in the age groups 55-64 years (23.6% of cases) and 65-74 years (24%). Mortality from STS was observed in the age groups 55-64 years (24.3% of cases) and 65-74 years (17.5%). Conclusion: SMTs are varied, and their diagnosis can be difficult in the early stages. The increasing incidence with age, especially in middle-aged people, emphasizes the importance of active prevention and early diagnosis in older people.
- 29 March 2024
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 71 (1)
EPIDEMIOLOGICAL SITUATION OF SKIN CANCER AND MELANOMIA IN THE REPUBLIC OF KAZAKHSTAN IN 2012-2022
Relevance: Skin cancer, including melanoma, is a major health problem and one of the most common cancers in the world. The study aimed to obtain a complete epidemiological picture of skin cancer and melanoma in the Republic of Kazakhstan for 11 years, including analysis of data for 2022, considering various parameters such as age, sex, ethnicity, region, and tumor type. Methods: The study used data from patients registered in the national cancer registry of the Republic of Kazakhstan from 2012 to 2022, diagnosed with skin carcinoma and skin melanoma (ICD-10 code: C44-C43). The number of skin carcinomas and melanoma cases is presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality rates were calculated using the world standard (World). Results: At the end of 2022, 19,714 and 2,689 patients were diagnosed with “Skin Cancer” or “Skin Melanoma” in the Republic of Kazakhstan, respectively. From 2012 to 2022, the incidence of skin cancer increased by 24% and melanoma by 15%. In 2022, the incidence of skin cancer and melanoma was higher among women by 24% and 26%, respectively. Mortality from skin cancer is in 23rd place, from melanoma in 21st place. Mortality rates from skin cancer and melanoma were 0.5 and 0.7 per 100 thousand population, respectively. The peak incidence of skin cancer in 2022 was observed in the age group 65-74 years (36%), and mortality in the age groups 65-74 and 75-84 years (17% each). The peak incidence of skin melanoma in 2022 was observed in the age groups 55-64 years and 65-74 years (24% and 25%), and mortality in the groups 45-54 years and 35-44 years (14% and 10%). Conclusion: There has been a steady increase in the incidence of skin cancer and melanoma, which indicates the seriousness of this problem in the country and underlines the need for further measures to prevent, diagnose and treat skin cancer and melanoma in the Republic of Kazakhstan. It should be remembered that many cases of skin cancer can be prevented with simple precautions.
- 29 March 2024
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 71 (1)
EPIDEMIOLOGICAL SITUATION OF SKIN CANCER AND MELANOMIA IN THE REPUBLIC OF KAZAKHSTAN IN 2012-2022
Relevance: Skin cancer, including melanoma, is a major health problem and one of the most common cancers in the world. The study aimed to obtain a complete epidemiological picture of skin cancer and melanoma in the Republic of Kazakhstan for 11 years, including analysis of data for 2022, considering various parameters such as age, sex, ethnicity, region, and tumor type. Methods: The study used data from patients registered in the national cancer registry of the Republic of Kazakhstan from 2012 to 2022, diagnosed with skin carcinoma and skin melanoma (ICD-10 code: C44-C43). The number of skin carcinomas and melanoma cases is presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality rates were calculated using the world standard (World). Results: At the end of 2022, 19,714 and 2,689 patients were diagnosed with “Skin Cancer” or “Skin Melanoma” in the Republic of Kazakhstan, respectively. From 2012 to 2022, the incidence of skin cancer increased by 24% and melanoma by 15%. In 2022, the incidence of skin cancer and melanoma was higher among women by 24% and 26%, respectively. Mortality from skin cancer is in 23rd place, from melanoma in 21st place. Mortality rates from skin cancer and melanoma were 0.5 and 0.7 per 100 thousand population, respectively. The peak incidence of skin cancer in 2022 was observed in the age group 65-74 years (36%), and mortality in the age groups 65-74 and 75-84 years (17% each). The peak incidence of skin melanoma in 2022 was observed in the age groups 55-64 years and 65-74 years (24% and 25%), and mortality in the groups 45-54 years and 35-44 years (14% and 10%). Conclusion: There has been a steady increase in the incidence of skin cancer and melanoma, which indicates the seriousness of this problem in the country and underlines the need for further measures to prevent, diagnose and treat skin cancer and melanoma in the Republic of Kazakhstan. It should be remembered that many cases of skin cancer can be prevented with simple precautions.
- 31 March 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 63 (1)
CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF BONE SARCOMAS IN THE REPUBLIC OF KAZAKHSTAN IN 2010-2019
Relevance: Sarcomas are a heterogeneous group of mesenchymal origin malignant neoplasms (MNs). The peak incidence of bone tumors falls at a socially significant age: with osteosarcoma and Ewing’s sarcoma – 10-25 years, with chondrosarcoma – 35-40 years. Bone sarcomas are the most aggressive human MNs. This urges to determine the prognostic factors of the disease, timely assess the treatment effect, and identify possible relapses. The study aimed to improve the early diagnosis of bone sarcomas, to improve and increase the oncological alertness of doctors by establishing the trends in bone sarcoma incidence and mortality in Kazakhstan in 2010-2019 and this disease incidence and mortality in 2019 by age, gender, bone tumor histotype and region of the country. Materials and Methods: This study included the data of all patients registered at the Electronic Registry of Oncological Patients (EROP) of the Republic of Kazakhstan in 2010-2019 with a “bone sarcoma” diagnosis (ICD-10 code: C40-C41). The incidence of bone sarcomas was presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality were calculated using the World Standard. MS Excel 2016 was used to display the results graphically. Results: By the end of 2019, 1587 patients were registered with bone sarcomas in Kazakhstan. From 2010 to 2019, the incidence of bone sarcoma in Kazakhstan decreased by 39%, including 36% among men and 40% among women. Mortality decreased by 37% to 0.7% per 100,000 population. Bone sarcoma is not among the 20 most common types of cancer in Kazakhstan. It accounts for 0.7% of all new cases of MN (2010-2019). The peak incidence of bone sarcoma was observed at the age below 20 years (20%), and mortality – was registered at 45-54 years (22%). Conclusion: The rare occurrence of bone MNs can cause misdiagnosis during the initial examination. Bone sarcomas account for 0.8% of all MNs diagnosed in Kazakhstan. However, the aggressiveness of the course and rapid hematogenous metastasis causes a high percentage of neglect of this disease during the initial visit. In addition, bone sarcomas are more common than other MNs in young adults and adolescents. Therefore, the prognosis of primary bone sarcomas depends on many factors.
- 31 March 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 63 (1)
CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF BONE SARCOMAS IN THE REPUBLIC OF KAZAKHSTAN IN 2010-2019
Relevance: Sarcomas are a heterogeneous group of mesenchymal origin malignant neoplasms (MNs). The peak incidence of bone tumors falls at a socially significant age: with osteosarcoma and Ewing’s sarcoma – 10-25 years, with chondrosarcoma – 35-40 years. Bone sarcomas are the most aggressive human MNs. This urges to determine the prognostic factors of the disease, timely assess the treatment effect, and identify possible relapses. The study aimed to improve the early diagnosis of bone sarcomas, to improve and increase the oncological alertness of doctors by establishing the trends in bone sarcoma incidence and mortality in Kazakhstan in 2010-2019 and this disease incidence and mortality in 2019 by age, gender, bone tumor histotype and region of the country. Materials and Methods: This study included the data of all patients registered at the Electronic Registry of Oncological Patients (EROP) of the Republic of Kazakhstan in 2010-2019 with a “bone sarcoma” diagnosis (ICD-10 code: C40-C41). The incidence of bone sarcomas was presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality were calculated using the World Standard. MS Excel 2016 was used to display the results graphically. Results: By the end of 2019, 1587 patients were registered with bone sarcomas in Kazakhstan. From 2010 to 2019, the incidence of bone sarcoma in Kazakhstan decreased by 39%, including 36% among men and 40% among women. Mortality decreased by 37% to 0.7% per 100,000 population. Bone sarcoma is not among the 20 most common types of cancer in Kazakhstan. It accounts for 0.7% of all new cases of MN (2010-2019). The peak incidence of bone sarcoma was observed at the age below 20 years (20%), and mortality – was registered at 45-54 years (22%). Conclusion: The rare occurrence of bone MNs can cause misdiagnosis during the initial examination. Bone sarcomas account for 0.8% of all MNs diagnosed in Kazakhstan. However, the aggressiveness of the course and rapid hematogenous metastasis causes a high percentage of neglect of this disease during the initial visit. In addition, bone sarcomas are more common than other MNs in young adults and adolescents. Therefore, the prognosis of primary bone sarcomas depends on many factors.
- 31 March 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 63 (1)
CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF BONE SARCOMAS IN THE REPUBLIC OF KAZAKHSTAN IN 2010-2019
Relevance: Sarcomas are a heterogeneous group of malignant neoplasms (MNs) of mesenchymal origin. The peak incidence of bone tumors falls on a socially significant age: with osteosarcoma and Ewing’s sarcoma – 10-25 years, with chondrosarcoma – 35-40 years. Bone sarcomas are the most aggressive human MNs. This urges to determine the prognostic factors of the disease, timely assess the treatment effect, and identify possible relapses. The study aimed to improve the early diagnosis of bone sarcomas, to improve and increase the oncological alertness of doctors by establishing the trends in bone sarcoma incidence and mortality in the Republic of Kazakhstan in 2010-2019, and this disease incidence and mortality in 2019 by age, gender, bone tumor histotype and region of the country. Methods: The study included the data of patients registered at the RK National Cancer Registry in 2010-2019 with a “bone sarcoma” diagnosis (ICD-10 code: C40-C41). The incidence of bone sarcomas was presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality were calculated using the World Standard. MS Excel 2016 was used to display the results graphically. Results: By the end of 2019, 1587 patients were registered with bone sarcomas in the RK. From 2010 to 2019, the incidence of bone sarcoma in the RK decreased by 39%, including 36% among men and 40% among women. Mortality decreased by 37% to 0.8% per 100,000 population. Bone sarcoma is not among the 20 most common types of cancer in the RK; it accounts for 0.7% of all new cases of MN (2010-2019). The peak incidence of bone sarcoma was observed at the age below 20 years (20%), and mortality – in the age group of 45-54 years (22%). Conclusion: The rare occurrence of bone MNs can cause misdiagnosis during the initial examination. Bone sarcomas account for 0.8% of all MNs diagnosed in the RK; however, the aggressiveness of the course and rapid hematogenous metastasis causes a high percentage of neglect of this disease during the initial visit. In addition, bone sarcomas are more common than other MNs in young adults and adolescents. The prognosis of primary bone sarcomas depends on many factors.
- 31 March 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 63 (1)
CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF BONE SARCOMAS IN THE REPUBLIC OF KAZAKHSTAN IN 2010-2019
Relevance: Sarcomas are a heterogeneous group of malignant neoplasms (MNs) of mesenchymal origin. The peak incidence of bone tumors falls on a socially significant age: with osteosarcoma and Ewing’s sarcoma – 10-25 years, with chondrosarcoma – 35-40 years. Bone sarcomas are the most aggressive human MNs. This urges to determine the prognostic factors of the disease, timely assess the treatment effect, and identify possible relapses. The study aimed to improve the early diagnosis of bone sarcomas, to improve and increase the oncological alertness of doctors by establishing the trends in bone sarcoma incidence and mortality in the Republic of Kazakhstan in 2010-2019, and this disease incidence and mortality in 2019 by age, gender, bone tumor histotype and region of the country. Methods: The study included the data of patients registered at the RK National Cancer Registry in 2010-2019 with a “bone sarcoma” diagnosis (ICD-10 code: C40-C41). The incidence of bone sarcomas was presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality were calculated using the World Standard. MS Excel 2016 was used to display the results graphically. Results: By the end of 2019, 1587 patients were registered with bone sarcomas in the RK. From 2010 to 2019, the incidence of bone sarcoma in the RK decreased by 39%, including 36% among men and 40% among women. Mortality decreased by 37% to 0.8% per 100,000 population. Bone sarcoma is not among the 20 most common types of cancer in the RK; it accounts for 0.7% of all new cases of MN (2010-2019). The peak incidence of bone sarcoma was observed at the age below 20 years (20%), and mortality – in the age group of 45-54 years (22%). Conclusion: The rare occurrence of bone MNs can cause misdiagnosis during the initial examination. Bone sarcomas account for 0.8% of all MNs diagnosed in the RK; however, the aggressiveness of the course and rapid hematogenous metastasis causes a high percentage of neglect of this disease during the initial visit. In addition, bone sarcomas are more common than other MNs in young adults and adolescents. The prognosis of primary bone sarcomas depends on many factors.